AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial -NIAID, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru., AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru., , Read More